TY - JOUR
T1 - New strategies in engineering T-cell receptor gene-modified T cells to more effectively target malignancies
AU - Schmitt, Thomas M.
AU - Stromnes, Ingunn M.
AU - Chapuis, Aude G.
AU - Greenberg, Philip D.
N1 - Publisher Copyright:
© 2015 American Association for Cancer Research.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - The immune system, T cells in particular, have the ability to target and destroy malignant cells. However, antitumor immune responses induced from the endogenous T-cell repertoire are often insufficient for the eradication of established tumors, as illustrated by the failure of cancer vaccination strategies or checkpoint blockade for most tumors. Genetic modification of T cells to express a defined T-cell receptor (TCR) can provide the means to rapidly generate large numbers of tumor-reactive T cells capable of targeting tumor cells in vivo. However, cell-intrinsic factors as well as immunosuppressive factors in the tumor microenvironment can limit the function of such gene-modified T cells. New strategies currently being developed are refining and enhancing this approach, resulting in cellular therapies that more effectively target tumors and that are less susceptible to tumor immune evasion.
AB - The immune system, T cells in particular, have the ability to target and destroy malignant cells. However, antitumor immune responses induced from the endogenous T-cell repertoire are often insufficient for the eradication of established tumors, as illustrated by the failure of cancer vaccination strategies or checkpoint blockade for most tumors. Genetic modification of T cells to express a defined T-cell receptor (TCR) can provide the means to rapidly generate large numbers of tumor-reactive T cells capable of targeting tumor cells in vivo. However, cell-intrinsic factors as well as immunosuppressive factors in the tumor microenvironment can limit the function of such gene-modified T cells. New strategies currently being developed are refining and enhancing this approach, resulting in cellular therapies that more effectively target tumors and that are less susceptible to tumor immune evasion.
UR - http://www.scopus.com/inward/record.url?scp=84954126580&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84954126580&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-15-0860
DO - 10.1158/1078-0432.CCR-15-0860
M3 - Article
C2 - 26463711
AN - SCOPUS:84954126580
SN - 1078-0432
VL - 21
SP - 5191
EP - 5197
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 23
ER -